Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Deeks

Showing results (111-120 of 663) with videos related to

Pageof 67
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|August 11, 2012
The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsMark R Underwood, Brian A Johns, Akihiko Sato, et al.
AIDS (London, England)|February 9, 2012
Association of tenofovir exposure with kidney disease risk in HIV infectionRebecca Scherzer, Michelle Estrella, Yongmei Li, et al.
Plos Computational Biology|December 3, 2010
Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral loadNaveen K Vaidya, Libin Rong, Vincent C Marconi, et al.
Journal of Virology|January 26, 2007
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitorsNeelanjana Ray, Jessamina E Harrison, Leslie A Blackburn, et al.
The Journal of Infectious Diseases|May 2, 2003
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapyPeter W Hunt, Jeffrey N Martin, Elizabeth Sinclair, et al.
Computational Statistics & Data Analysis|September 28, 2011
Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatmentChristina M R Kitchen, Jing Kroll, Daniel R Kuritzkes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2018
Differential Expression of CD8<sup>+</sup> T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 InfectionBrenna E Kiniry, Peter W Hunt, Frederick M Hecht, et al.
The Journal of Infectious Diseases|February 6, 2018
Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?Peter D Burbelo, Richard W Price, Lars Hagberg, et al.
AIDS Research and Therapy|September 3, 2014
Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV diseaseLillian Seu, Gabriel M Ortiz, Trevor D Burt, et al.
Plos One|December 5, 2012
Lack of evidence for mtDNA as a biomarker of innate immune activation in HIV infectionAdam S Lauring, Tzong-Hae Lee, Jeffrey N Martin, et al.
Pageof 67

Showing results (111-120 of 663) with videos related to

Sort By:
Pageof 67
Journal of Acquired Immune Deficiency Syndromes (1999)|August 11, 2012
The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsMark R Underwood, Brian A Johns, Akihiko Sato, et al.
AIDS (London, England)|February 9, 2012
Association of tenofovir exposure with kidney disease risk in HIV infectionRebecca Scherzer, Michelle Estrella, Yongmei Li, et al.
Plos Computational Biology|December 3, 2010
Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral loadNaveen K Vaidya, Libin Rong, Vincent C Marconi, et al.
Journal of Virology|January 26, 2007
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitorsNeelanjana Ray, Jessamina E Harrison, Leslie A Blackburn, et al.
The Journal of Infectious Diseases|May 2, 2003
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapyPeter W Hunt, Jeffrey N Martin, Elizabeth Sinclair, et al.
Computational Statistics & Data Analysis|September 28, 2011
Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatmentChristina M R Kitchen, Jing Kroll, Daniel R Kuritzkes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2018
Differential Expression of CD8<sup>+</sup> T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 InfectionBrenna E Kiniry, Peter W Hunt, Frederick M Hecht, et al.
The Journal of Infectious Diseases|February 6, 2018
Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?Peter D Burbelo, Richard W Price, Lars Hagberg, et al.
AIDS Research and Therapy|September 3, 2014
Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV diseaseLillian Seu, Gabriel M Ortiz, Trevor D Burt, et al.
Plos One|December 5, 2012
Lack of evidence for mtDNA as a biomarker of innate immune activation in HIV infectionAdam S Lauring, Tzong-Hae Lee, Jeffrey N Martin, et al.
Pageof 67